# Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

> **NCT06727565** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 100 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Domvanalimab
- **DRUG:** Zimberelimab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06727565
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-18
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06727565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06727565, "Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT06727565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*